Hokkaido University · 医学
Sawa教授の研究室は、ウイルスの感染メカニズムと抗ウイルス薬の開発を柱としており、特にJCウイルスの宿主細胞への結合機構やSARS-CoV-2の主プロテアーゼを標的にした経口抗ウイルス薬の創出を進めています。ウイルスの糖鎖結合機構の解明から、臨床応用に結びつく創薬開発までを網羅するトータルなウイルス研究を展開しています。
Figures are computed from collected data and may differ slightly.
JC virus (JCV) belongs to the polyomavirus family of double-stranded DNA viruses and in humans causes a demyelinating disease of the central nervous system, progressive multifocal leukoencephalopathy. Its hemagglutination activity and entry into host cells have been reported to depend on an N-linked glycoprotein containing sialic acid. In order to identify the receptors of JCV, we generated virus-like particles (VLP) consisting of major viral capsid protein VP1. We then developed an indirect VLP
In parallel with vaccination, oral antiviral agents are highly anticipated to act as countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oral antiviral medication demands not only high antiviral activity but also target specificity, favorable oral bioavailability, and high metabolic stability. Although a large number of compounds have been identified as potential inhibitors of SARS-CoV-2 inf
Open papers in the app to read, cite, and organize with AI.
